The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail.

This List shall come into effect on 1 January 2019
IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS "SPECIFIED SUBSTANCES" EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3.

PROHIBITED SUBSTANCES

S0 NON-APPROVED SUBSTANCES
Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

S1 ANABOLIC AGENTS
Anabolic agents are prohibited.

1. ANABOLIC ANDROGENIC STEROIDS (AAS)
   a. Exogenous* AAS, including:

   1-Androstenediol \(5\alpha\)-androst-1-ene-3\(\beta\),17\(\beta\)-diol);
   1-Androstenedione \(5\alpha\)-androst-1-ene-3,17-dione);
   1-Androsterone \(3\alpha\)-hydroxy-5\(\alpha\)-androst-1-ene-17-one);
   1-Testosterone \(17\beta\)-hydroxy-5\(\alpha\)-androst-1-en-3-one);
   Bolasterone;
   Calusterone;
   Clostebol;
   Danazol \([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17\alpha\-ol);
   Dehydrochlormethyltestosterone \(4\)-chloro-17\(\beta\)-hydroxy-17\(\alpha\)-methylandrosta-1,4-dien-3-one);
   Desoxymethyltestosterone \(17\alpha\)-methyl-5\(\alpha\)-androst-2-en-17\(\beta\)-ol and 17\(\alpha\)-methyl-5\(\alpha\)-androst-3-en-17\(\beta\)-ol);
   Drostanolone;
   Ethylestrenol \(19\)-norpregna-4-en-17\(\alpha\)-ol);
   Fluoxymesterone;
   Formebolone;
   Furazabol \(17\alpha\)-methyl \([1,2,5]oxadiazolo[3',4':2,3]5\(\alpha\)-androstan-17\(\beta\)-ol);
   Gestrinone;
   Mesterolone;
   Metandienone \(17\beta\)-hydroxy-17\(\alpha\)-methylandrosta-1,4-dien-3-one);
   Metenolone;
   Methandriol;
   Methasterone \(17\beta\)-hydroxy-2\(\alpha\),17\(\alpha\)-dimethyl-5\(\alpha\)-androstan-3-one);
   Methyldienolone \(17\beta\)-hydroxy-17\(\alpha\)-methylenestra-4,9-dien-3-one);
   Methyl-1-testosterone \(17\beta\)-hydroxy-17\(\alpha\)-methyl-5\(\alpha\)-androst-1-en-3-one);
   Methyltestosterone; Metribolone \(methyltrienolone, 17\beta\)-hydroxy-17\(\alpha\)-methylenestra-4,9,11-trien-3-one);
   Mibolerone;
   Norboleton;
   Norclostebol;
   Norethandrolone;
   Oxabolone;
   Oxandrolone;
   Oxymesterone;
   Oxymetholone;
   Prostanozol \(17\beta\)-[[tetrahydropyran-2-yl]oxy]-1'H-pyrazolo[3,4,2,3]5\(\alpha\)-androstan); Quinbolone;
   Stanozolol;
   Stenbolone;
   Tetrahydrogestrinone \(17\)-hydroxy-18\(\alpha\)-homo-19-nor-17\(\alpha\)-pregna-4,9,11-trien-3-one);
   Trenbolone \(17\beta\)-hydroxyestra-4,9,11-trien-3-one);
   and other substances with a similar chemical structure or similar biological effect(s).
b. Endogenous** AAS and their Metabolites and isomers, when administered exogenously, including but not limited to:

4-A

Androstenediol [androst-4-ene-3β,17β-diol];
4-Hydroxytestosterone [4,17β-dihydroxyandrost-4-en-3-one];
5-Androstenedione [androst-5-ene-3,17-dione];
7α-hydroxy-DHEA;
7β-hydroxy-DHEA;
7-keto-DHEA;
19-Norandrostenediol [estr-4-ene-3,17-diol];
19-Norandrostenedione [estr-4-ene-3,17-dione];
Androstanolone (5α-dihydrotestosterone, 17β-hydroxy-5α-androstan-3-one);
Androstenediol [androst-5-ene-3β,17β-diol];
Androstenedione [androst-4-ene-3,17-dione];
Boldenone;
Boldione [androsta-1,4-diene-3,17-dione];
Epandrosterone (3β-hydroxy-5α-androstan-17-one);
Epi-dihydrotestosterone (17β-hydroxy-5β-androstan-3-one);
Epitestosterone;
Nandrolone (19-nortestosterone);
Prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one);
Testosterone.

-----------------------------------------------------------------------------------

2. OTHER ANABOLIC AGENTS

Including, but not limited to:
Clenbuterol, selective androgen receptor modulators (SARMs, e.g. andarine, LGD-4033, enobosarm [ostarine] and RAD140), tibolone, zeranol and zilpaterol.

For purposes of this section:
* “exogenous” refers to a substance which is not ordinarily produced by the body naturally.
** “endogenous” refers to a substance which is ordinarily produced by the body naturally.
2. Peptide Hormones and their Releasing Factors,
   2.1 Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors in males, e.g. Buserelin, deslorelin, gonadorelin, goserelin, leuprorelin, nafarelin and triptorelin;
   2.2 Corticotrophins and their releasing factors, e.g. Corticorelin;
   2.3 Growth Hormone (GH), its fragments and releasing factors, including, but not limited to: Growth Hormone fragments, e.g. AOD-9604 and hGH 176-191; Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin; Growth Hormone Secretagogues (GHS), e.g. lenomorelin (ghrelin) and its mimetics, e.g. anamorelin, ipamorelin, macimorelin and tabimorelin; GH-Releasing Peptides (GHRPs), e.g. alexamorelin, GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and examorelin (hexarelin).

3. Growth Factors and Growth Factor Modulators, including, but not limited to:
   Fibroblast Growth Factors (FGFs);
   Heparocyte Growth Factor (HGF);
   Insulin-like Growth Factor-1 (IGF-1) and its analogues;
   Mechano Growth Factors (MGFs);
   Platelet-Derived Growth Factor (PDGF);
   Thymosin-β4 and its derivatives e.g. TB-500;
   Vascular-Endothelial Growth Factor (VEGF);
and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/ degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.

### BETA-2 AGONISTS

All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Including, but not limited to:
- Fenoterol;
- Formoterol;
- Higenamine;
- Indacaterol;
- Olodaterol;
- Procaterol;
- Reproterol;
- Salbutamol;
- Salmeterol;
- Terbutaline;
- Tretoquinol (trimetoquinol);
- Tulobuterol;
- Vilanterol.

**Except:**
- Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 800 micrograms over 12 hours starting from any dose;
- Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours;
- Inhaled salmeterol: maximum 200 micrograms over 24 hours.

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an **Adverse Analytical Finding (AAF)** unless the **Athlete** proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above.
**HORMONE AND METABOLIC MODULATORS**

The following hormone and metabolic modulators are prohibited:

1. Aromatase inhibitors including, but not limited to:
   - 2-Androstenol (5α-androst-2-en-17-ol);
   - 2-Androstenone (5α-androst-2-en-17-one);
   - 3-Androstenol (5α-androst-3-en-17-ol);
   - 3-Androstenone (5α-androst-3-en-17-one);
   - 4-Androstene-3,6,17 trione (6-oxo);
   - Aminoglutethimide;
   - Anastrozole;
   - Androsta-1,4,6-triene-3,17-dione (androstatrienedione);
   - Androsta-3,5-diene-7,17-dione (arimistane);
   - Exemestane;
   - Formestane;
   - Letrozole;
   - Testolactone.

2. Selective estrogen receptor modulators (SERMs) including, but not limited to:
   - Raloxifene;
   - Tamoxifen;
   - Toremifene.

3. Other anti-estrogenic substances including, but not limited to:
   - Clomifene;
   - Cyclofenil;
   - Fulvestrant.

4. Agents preventing activin receptor IIB activation including, but not limited to:
   - Activin A-neutralizing antibodies;
   - Activin receptor IIB competitors such as:
     - Decoy activin receptors (e.g. ACE-031);
   - Anti-activin receptor IIB antibodies (e.g. bimagrumab);
   - Myostatin inhibitors such as:
     - Agents reducing or ablating myostatin expression;
     - Myostatin-binding proteins (e.g. follistatin, myostatin propeptide);
     - Myostatin-neutralizing antibodies (e.g. domagrozumab, landogrozumab, stamulumab).

5. Metabolic modulators:
   - 5.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, SR9009; and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists, e.g. 2-(2-methyl-4-[(4-methyl-2-[4-[trifluoromethyl] phenyl]thiazol-5-yl)methylthio]phenoxo) acetic acid (GW1516, GW501516);
   - 5.2 Insulins and insulin-mimetics;
   - 5.3 Meldonium;
   - 5.4 Trimetazidine.

**DIURETICS AND MASKING AGENTS**

The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s).

Including, but not limited to:

- Desmopressin; probenecid; plasma expanders, e.g. intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol.
- Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflu- methiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan.

Except:

- Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide);
- Local administration of felypressin in dental anaesthesia.

The detection in an Athlete's Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an **Adverse Analytical Finding (AAF)** unless the Athlete has an approved **Therapeutic Use Exemption (TUE)** for that substance in addition to the one granted for the diuretic or masking agent.
PROHIBITED METHODS

M1 MANIPULATION OF BLOOD AND BLOOD COMPONENTS
The following are prohibited:
1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system.

2. Artificially enhancing the uptake, transport or delivery of oxygen.
Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation.

3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

M2 CHEMICAL AND PHYSICAL MANIPULATION
The following are prohibited:
1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control.
Including, but not limited to:
Urine substitution and/or adulteration, e.g. proteases.

2. Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations.

M3 GENE AND CELL DOPING
The following, with the potential to enhance sport performance, are prohibited:
1. The use of polymers of nucleic acids or nucleic acid analogues.

2. The use of gene editing agents designed to alter genome sequences and/or the transcriptional, post-transcriptional or epigenetic regulation of gene expression.

3. The use of normal or genetically modified cells.
IN ADDITION TO THE CLASSES S0 TO S5 AND M1 TO M3 DEFINED ABOVE, THE FOLLOWING CLASSES ARE PROHIBITED IN-COMPETITION:

PROHIBITED SUBSTANCES

STIMULANTS
All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited.

Stimulants include:

a: Non-Specified Stimulants:
- Adrafinil;
- Amfebramatone;
- Amfetamine;
- Amfetaminil;
- Amifiphenazone;
- Amfetamine;
- Benfluorex;
- Benzyfpiperazine;
- Bromantan;
- Clobenzorex;
- Cocaine;
- Cropropamide;
- Crotetamide;
- Fencamine;
- Fenetylline;
- Fenfluramine;
- Fenproporex;
- Fonturacetam [4-phenylpiracetam (carphedon)];
- Furfenorex;
- Isometheptene;
- Levmetamfetamine;
- Mefenorex;
- Mefenorex;
- Methylenedioxymethamphetamine;
- Methylephedrine***;
- Methylenedioxymethamphetamine;
- Methylephedrine***;
- Methylephedrine****;
- Mephentermine;
- Mesocarb;
- Metamfetamine(d-);
- p-methylamfetamine;
- Modafinil;
- Norfenfluoramine;
- Phendimetrazine;
- Phentermine;
- Prenylamine;
- Prolintane.

A stimulant not expressly listed in this section is a Specified Substance.

b: Specified Stimulants.
Including, but not limited to:

- 3-Methylhexan-2-amine (1,2-dimethylpentylamine);
- 4-Methylhexan-2-amine (methylhexaneamine);
- 4-Methylpentan-2-amine (1,3-dimethylbutylamine);
- 5-Methylhexan-2-amine (1,4-dimethylpentylamine);
- Benzeftamine;
- Cathine**;
- Cathinone and its analogues, e.g. mephedrone,
methedrone, and α – pyrrolidinovalephopine;
- Dimetamfetamine [dimethylamphetamine];
- Ephedrine***;
- Epinephrine**** [adrenaline];
- Etamivan;
- Etileamfetamine;
- Etilefrine;
- Fampofazon;
- Fenbutrazate;
- Fencamfamin;
- Heptaminol;
- Hydroxyamfetamine [parahydroxyamphetamine];
- Isometheptene;
- Levmetamfetamine;
- Meclofenoxate;
- Methylephedrine****;
- Methylphenidate;
- Nikethamide;
- Norfenefrine;
- Octopamine;
- Oxilofrine (methylsynephrine);
- Pemoline;
- Pentetrazol;
- Phenethylamine and its derivatives;
- Phenmetrazine;
- Phenpromethamine;
- Propylhexedrine;
- Pseudoephedrine*****;
Selegiline;
Sibutramine;
Strychnine;
Tetrahydroamfetamine (methylendioxyamphetamine);
Tuaminoheptane;

and other substances with a similar chemical structure
or similar biological effect(s).

Except:
• Clonidine;
• Imidazole derivatives for topical/ophthalmic use
  and those stimulants included in the 2019
  Monitoring Program*.

*   Bupropion, caffeine, nicotine, phenylephrine,
  phenylpropanolamine, pipradrol, and synephrine: These
  substances are included in the 2019 Monitoring Program, and
  are not considered Prohibited Substances.
**  Cathine: Prohibited when its concentration in urine is greater
  than 5 micrograms per milliliter.
*** Ephedrine and methylephedrine: Prohibited when the
  concentration of either in urine is greater than 10 micrograms
  per milliliter.
**** Epinephrine (adrenaline): Not prohibited in local administration,
  e.g. nasal, ophthalmologic, or co-administration with local
  anaesthetic agents.
***** Pseudoephedrine: Prohibited when its concentration in urine
  is greater than 150 micrograms per milliliter.

---

**NARCOTICS**

The following narcotics are prohibited:
Buprenorphine;
Dextromoramide;
Diamorphine (heroin);
Fentanyl and its derivatives;
Hydromorphone;
Methadone;
Morphine;
Nicomorphine;
Oxycodone;
Oxymorphone;
Pentazocine;
Pethidine.

---

**CANNABINOIDS**

The following cannabinoids are prohibited:
• Natural cannabinoids, e.g. cannabis, hashish and
  marijuana,
• Synthetic cannabinoids e.g. Δ9-tetrahydrocannabinol
  (THC) and other cannabimimetics.

Except:
• Cannabidiol.

---

**GLUCOCORTICOIDS**

All glucocorticoids are prohibited when administered
by oral, intravenous, intramuscular or rectal routes.

Including but not limited to:
Betamethasone;
Budesonide;
Cortisone;
Deflazacort;
Dexamethasone;
Fluticasone;
Hydrocortisone;
Methylprednisolone;
Prednisolone;
Prednisone;
Triamcinolone.
SUBSTANCES PROHIBITED IN PARTICULAR SPORTS

P1 BETA-BLOCKERS

Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated.

- Archery [WA]*
- Automobile [FIA]
- Billiards [all disciplines] (WCBS)
- Darts [WDF]
- Golf [IGF]
- Shooting [ISSF, IPC]*
- Skiing/Snowboarding [FIS] in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air
- Underwater sports [CMAS] in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting, and variable weight apnoea.

*Also prohibited Out-of-Competition

Including, but not limited to:

- Acebutolol;
- Alpenolol;
- Atenolol;
- Betaxolol;
- Bisoprolol;
- Bunolol;
- Carteolol;
- Carvedilol;
- Celiprolol;
- Esmolol;
- Labetalol;
- Metipranolol;
- Metoprolol;
- Nadolol;
- Oxprenolol;
- Pindolol;
- Propranolol;
- Sotalol;
- Timolol.